Pfizer can’t get discovery in anticipation of Sandoz’ Enbrel biosimilar, judge says

Appeals 2020-12-03 11:00 pm By Cat Fredenburgh | Melbourne

Please login to bookmark

A judge hearing Pfizer’s application for preliminary discovery against Sandoz over its possible launch of an Enbrel biosimilar has found that such an application must be based on a current belief that the applicant could be entitled to relief.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au